Matthew Hall, PA
Medical · Adrian, MINPI 1699792176
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 441 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 441 payments — averaging $17.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$1K
- Pfizer$946
- AbbVie$910
- Lilly USA, LLC$787
- Exact Sciences$372
- plus $2K from 25 others
What the payments were for
- Food & beverage$7,535100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 83 | $1,329 |
| AstraZeneca | 59 | $1,063 |
| Pfizer | 49 | $946 |
| AbbVie | 64 | $910 |
| Lilly USA, LLC | 43 | $787 |
| Exact Sciences | 20 | $372 |
| Otsuka America Pharmaceutical, Inc. | 19 | $269 |
| Boehringer Ingelheim | 12 | $241 |
| Amgen | 11 | $179 |
| Amarin Pharma, Inc. | 10 | $155 |
| Dexcom, Inc. | 5 | $154 |
| E.r. Squibb & Sons, L.L.C. | 8 | $142 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $135 |
| GSK | 7 | $113 |
| Lundbeck LLC | 5 | $92 |
| Biohaven Pharmaceuticals, Inc. | 5 | $89 |
| Johnson & Johnson | 6 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $76 |
| Axsome Therapeutics, Inc. | 3 | $63 |
| Currax Pharmaceuticals LLC | 4 | $61 |
| Kowa Pharmaceuticals America, Inc. | 4 | $51 |
| Abbott | 2 | $38 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Merck | 2 | $34 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Bayer | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Corcept Therapeutics | 1 | $19 |
| Bausch Health US, LLC | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
How this compares
$7,558 in reported general payments places this provider in the 90th percentile of 755 medical providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 115 | $98,563 |
| OzempicSemaglutide | 43 | $56,633 |
| JanuviaSitagliptin Phosphate | 35 | $45,369 |
| JardianceEmpagliflozin | 25 | $40,115 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 30 | $34,762 |
| XareltoRivaroxaban | 29 | $31,352 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $24,369 |
| SynjardyEmpagliflozin/Metformin Hcl | 20 | $18,260 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $11,572 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 19 | $8,953 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $7,607 |
| Atorvastatin Calcium | 479 | $5,847 |
| Levothyroxine Sodium | 432 | $5,414 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 148 | $5,232 |
| Varenicline Tartrate | 25 | $4,980 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Combivent Respimat | $241 | $102,09094 claims |
| PfizerEliquis | $946 | $98,563115 claims |
| Novo NordiskOzempic | $1,329 | $56,63343 claims |
| MerckJanuvia | $34 | $45,36935 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $113 | $35,94155 claims |
| Johnson & JohnsonXarelto | $85 | $31,35229 claims |
| AstraZenecaSymbicort | $1,063 | $4,72822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 755 medical providers in Michigan.
Other medical in Adrian
- Louise JustusAdrian$8K
- Caleb YoungbloodBerkley$215K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$56K
- David WilkinsMuskegon$41K
- Mark RosenBerkley$32K
- Robert DemeesterRoyal Oak$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.